Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

Liaquat University of Medical & Health Sciences

Status and phase: Completed; Phase 3

Conditions: COVID-19

Treatments: Drug: Standard COVID-19 care; Dietary Supplement: Quercetin Phytosome

Study type: Interventional

Funder types: Other

Identifiers

NCT04578158

LUMHS/REC/894

Details and patient eligibility

About

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

Full description

This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30 days. It is proposed that Quercetin Phytosome will contribute to boosting the natural immunity of the subjects and will help in preventing the COVID-19 disease progression i.e preventing the need of hospitalisation.

Enrollment: 152 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years of either gender
• Confirmed SARS-CoV-2 infection by RT-PCR
• Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in self-isolation within 3 days of SARS-CoV-2 infection.
• Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous cough, a loss or change to sense of smell or taste
• Patients who have signed informed consent.

Exclusion criteria

• Patients with proven hypersensitivity or allergic reaction to quercetin
• Manifest contrary will

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

152 participants in 2 patient groups

Standard of care

Active Comparator group

Description:

This arm will receive the standard COVID-19 care as per the hospital physician guidelines.

Treatment:

Drug: Standard COVID-19 care

Quercetin Phytosome

Experimental group

Description:

This arm will receive standard COVID-19 care + Quercetin Phytosome

Treatment:

Drug: Standard COVID-19 care

Dietary Supplement: Quercetin Phytosome